Form 8-K Repare Therapeutics Inc. For: Aug 01
Repare Therapeutics Inc. - Common Shares (RPTX)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
RPTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPTX alerts
High impacting Repare Therapeutics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
RPTX
News
- CNL’S CNRI-H Program Continues Strong Growth Thanks to New Projects With Repare Therapeutics and Defence Therapeutics [Canadian Business Journal (Canada)]Canadian Business Journal
- Repare Therapeutics Inc. (NASDAQ: RPTX) was downgraded by analysts at Bloom Burton from a "strong-buy" rating to a "hold" rating.MarketBeat
- Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost ReductionsBusiness Wire
- Repare Therapeutics Inc. (NASDAQ: RPTX) had its "market perform" rating re-affirmed by analysts at Lifesci Capital.MarketBeat
- Repare Therapeutics eyes Phase III cancer study after Mythic trial success [Yahoo! Finance]Yahoo! Finance
RPTX
Earnings
- 2/28/24 - Miss
RPTX
Sec Filings
- 2/14/25 - Form SCHEDULE
- 1/31/25 - Form SCHEDULE
- 1/15/25 - Form SCHEDULE
- RPTX's page on the SEC website